RecruitingPHASE1, PHASE2NCT01269853

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Northwell Health
Principal Investigator
John Boockvar, MD
Feinstein Institute for Medical Research
Intervention
Bevacizumab(drug)
Enrollment
54 enrolled
Eligibility
18 years · All sexes
Timeline
20102027

Study locations (1)

Collaborators

Feinstein Institute for Medical Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01269853 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma

← Back to all trials